Ledermann, Jonathan A <br/><br/>
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.  [electronic resource] 

 -  The Lancet. Oncology  05 2020 
 - 710-722 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(20)30061-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Carcinoma--drug therapy<br/>Disease Progression<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Indoles--administration & dosage<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Platinum--administration & dosage<br/>Poly(ADP-ribose) Polymerase Inhibitors--administration & dosage<br/>Progression-Free Survival<br/>Treatment Outcome